We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Diagnostics Rapidly Gain Ground in Infectious Diseases Sector

By LabMedica International staff writers
Posted on 22 Dec 2014
Print article
According to a new Frost & Sullivan (Mountain View, CA, USA) analysis, convergence of immunological and molecular tests will help meet growing needs for infectious disease (ID) diagnostics. Although these tests remain expensive, their efficiency and accuracy strengthen their use case.

Frost & Sullivan’s new report “Analysis of the Global Infectious Disease Diagnostics Market” finds the market earned USD 7.91 billion revenue in 2013 and estimates it to reach USD 12.77 billion in 2018. Hepatitis B, hepatitis C, tuberculosis, and sepsis tests are predicted to be the major revenue generators.

The market will continue to develop as unmet technological needs lead to the creation of faster, more capable platforms. Molecular ID-diagnostics is growing fastest, clocking a compound annual growth of 15.3%. “Immunodiagnostics is another segment that continues to expand rapidly owing to cost-effective tests as well as the prevalence of hospital-acquired infections like sepsis and MRSA,” said Frost & Sullivan life sciences industry analyst Aish Vivekanandan, “Molecular methods and immunodiagnostics are expected to complement each other as the need for accurate and rapid diagnostic tests rises.”

Unique disease outbreaks across the globe are further escalating the demand for screening, spurring the ID diagnostic market. While decentralized and rapid tests are a growing trend in the developed world, stringent regulations complicate product development and marketing, and high costs affect the market in developing countries. Another challenge is low product awareness across regions. Companies must invest in clinical studies to prove the efficacy of their products and raise awareness among evidence-driven consumers, especially in the clinical field.

“Many participants are focusing their research on top industry requirements such as product automation, rapidity, specificity, and accuracy,” noted Vivekanandan, “Companies are also striving to expand the scope of diseases their products cover in order to establish their foothold in the global ID diagnostics market.”

The new report is part of Frost & Sullivan’s Life Sciences Growth Partnership Service program. Related studies include: “Global in Vitro Diagnostics Market,” “US Hematology Diagnostics Market,” “Global Next-generation Sequencing Market,” and “Western European Companion Diagnostics Market.” All studies included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

Related Links:
Frost & Sullivan
Analysis of the Global Infectious Disease Diagnostics Market report
Life Sciences Growth Partnership Service program


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The real-time multiplex PCR test is set to revolutionize early sepsis detection (Photo courtesy of Shutterstock)

1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens

Sepsis contributes to one in every three hospital deaths in the US, and globally, septic shock carries a mortality rate of 30-40%. Diagnosing sepsis early is challenging due to its non-specific symptoms... Read more

Pathology

view channel
Image: The QIAseq xHYB Mycobacterium tuberculosis Panel uses next-generation sequencing (Photo courtesy of 123RF)

New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance

Tuberculosis (TB), the leading cause of death from an infectious disease globally, is a contagious bacterial infection that primarily spreads through the coughing of patients with active pulmonary TB.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.